Earnings Call Summary | Bio-Techne(TECH.US) Q3 2024 Earnings Conference
Earnings Call Summary | Bio-Techne(TECH.US) Q3 2024 Earnings Conference
The following is a summary of the Bio-Techne Corporation (TECH) Q3 2024 Earnings Call Transcript:
以下是生物技術公司（TECH）2024年第三季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
Bio-Techne Corporation reported a 2% year-over-year organic revenue growth in Q3.
Adjusted operating margin increased to 33%, up by 290 basis points compared to the previous year.
Adjusted EPS was $0.48 for the quarter, a decrease compared to $0.53 from the same quarter last year.
Cash from operations reached $81 million for the quarter.
The company observed improvements in demand from both North American and European regions.
Bio-Techne公司報告稱，第三季度有機收入同比增長2％。
調整後的營業利潤率提高到33％，與去年相比增長了290個點子。
本季度調整後的每股收益爲0.48美元，與去年同期的0.53美元相比有所下降。
本季度運營現金達到8,100萬美元。
該公司觀察到北美和歐洲地區的需求都有所改善。
Business Progress:
業務進展：
There was a 30% increase in cell and gene therapy product and services for the quarter.
The company's liquid biopsy platform, especially the ExoDx Prostate test, exhibited 25% volume growth.
Bio-Techne won awards for excellence and its RNAScope technology surpassed 10,000 customer publications.
Growth improvement was noted in the biopharma sector and Chinese market.
The company plans to expand its GMP reagent portfolio and implement AI capabilities to create patentable proteins and reagents.
Plans to launch exosome-based single gene mutation tests for cancer markers monitoring were announced.
The company is focusing on growing its presence in the cell and gene therapy market. A strategic partnership with Wilson Wolf for reagent supply in clinical trials and an expansion of the Fisher agreement into Europe speaks to the company's growth plans.
Bio-Techne's organic growth for Q3 2024 was four points better than initial guidance due to a rebound in cell and gene therapy and successful performances from their proteomics instrument portfolio.
The company is looking to increase in-house capacity due to increased orders and growing market traction for their ScaleReady solution.
本季度細胞和基因療法產品和服務增長了30％。
該公司的液體活檢平台，尤其是ExoDx前列腺檢測，量增長了25％。
Bio-Techne憑藉卓越表現獲得了獎項，其RNAScope技術超過了10,000份客戶出版物。
生物製藥行業和中國市場的增長有所改善。
該公司計劃擴大其GMP試劑產品組合，並實現人工智能功能，以創建可獲得專利的蛋白質和試劑。
宣佈了啓動基於外泌體的單基因突變測試以監測癌症標誌物的計劃。
該公司正專注於擴大其在細胞和基因療法市場的影響力。與威爾遜·沃爾夫就臨床試驗中的試劑供應建立戰略合作伙伴關係，並將費舍爾協議擴展到歐洲，這表明了該公司的增長計劃。
由於細胞和基因療法的反彈以及其蛋白質組學儀器產品組合的成功表現，Bio-Techne在2024年第三季度的有機增長比最初的預期好四個百分點。
由於其ScaleReady解決方案的訂單增加和市場吸引力的提高，該公司正在尋求增加內部產能。
More details: Bio-Techne IR
更多詳情： 生物技術紅外線
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。